問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result > Study Site

Study Site



Linkou Chang Gung Medical Foundation

  • 0

    Total Beds

  • 0

    Total Doctors

  • 244New Taipei CityLinkou

Recruiting Trial

916Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

2341Cases

2025-04-04 - 2029-12-07

Phase I/II

Completed
A Phase Ib/II Dose Finding Study Assessing Safety and Efficacy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination with Carboplatin, Etoposide and Atezolizumab in Induction and with Atezolizumab in Maintenance Phase

  • Condition/Disease

    Extensive Stage Small Cell Lung Cancer

  • Test Drug

    LUTATHERA® (AAA601) NETSPOT® (AAA501)

Participate Sites
3Sites

Recruiting3Sites

2025-08-01 - 2032-12-31

Phase III

Active
AcTFirst: A phase III, open-label, multi-center, randomized study comparing AAA817+ARPI versus standard of care in adult participants with PSMA-positive metastatic castration resistant prostate cancer

  • Condition/Disease

    The purpose of this study is to determine whether [225Ac]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression free survival (rPFS) compared to investigator's choice of standard of care (SOC) (ARPI change or taxane-based chemotherapy or [177Lu]Lu-PSMA-617 (AAA617)) in adult participants with PSMA-positive metastatic castration resistant prostate cancer (mCRPC) treated with another ARPI as last treatment and who have not been exposed to a taxane-containing chemotherapy in the mCRPC setting nor have received any prior PSMA-targeting radioligand therapy.

  • Test Drug

    AAA617 AAA817 Abiraterone Cabazitaxel

Participate Sites
5Sites

Recruiting5Sites

2025-09-15 - 2036-04-30

Phase III

Not yet recruiting
A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients with BRCAm Localised High-Risk Prostate Cancer Receiving Radiotherapy with Androgen Deprivation Therapy (EvoPAR-Prostate02)

  • Condition/Disease

    Prostate Cancer

  • Test Drug

    AZD5305

Participate Sites
8Sites

Recruiting8Sites

2025-09-01 - 2029-12-31

Phase III

Active
A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer

  • Condition/Disease

    Metastatic Castration-resistant Prostatic Neoplasms

  • Test Drug

    JNJ-78278343 (Pasritamig)

Participate Sites
7Sites

Recruiting7Sites

2025-10-01 - 2028-12-31

Active
A Phase IIb Randomized, Double-blind, Placebo-controlled, Parallel, Multidose Study to Evaluate the Efficacy, Safety, and PK of AZD0292 in Participants 12 years of Age and Older With Bronchiectasis and Chronic Pseudomonas aeruginosa Colonization

  • Condition/Disease

    Bronchiectasis With Pseudomonas Aeruginosa Colonization

  • Test Drug

    AZD0292

Participate Sites
7Sites

Recruiting7Sites

2025-11-01 - 2028-12-31

Phase III

Active
A Multicenter Platform Study on the Safety, Tolerability, Bioactivity, and Pharmacokinetics of Intravitreal Therapies in Retinal Vascular and Inflammatory Diseases

  • Condition/Disease

    Macular Edema Secondary to Inflammation

  • Test Drug

    KSI-101

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting4Sites

2026-01-16 - 2033-12-31

Phase III

Active
A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOT-ov85/GOG-3102)

  • Condition/Disease

    Ovarian Neoplasms Ovarian Cancer

  • Test Drug

    MK-2870 艾法施®/MVASI®

Participate Sites
5Sites

Recruiting5Sites

2026-01-01 - 2032-03-10

Phase III

Active
A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants with Metabolic Dysfunction-Associated Steatotic Liver Disease who are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes)

  • Condition/Disease

    Metabolic Dysfunction-Associated Steatotic Liver Disease

  • Test Drug

    Retatrutide (LY3437943) Tirzepatide (LY3298176)

Participate Sites
15Sites

Not yet recruiting8Sites

Recruiting7Sites

2026-01-27 - 2030-12-31

Phase II

Active
A Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06F

  • Condition/Disease

    Oesophageal Squamous Cell Carcinoma

  • Test Drug

    ifinatamab deruxtecan (I-DXd)

Participate Sites
7Sites

Recruiting7Sites

2025-11-01 - 2034-12-31

Phase III

Active
A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants with Advanced RCC who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)

  • Condition/Disease

    Renal Cell Carcinoma

  • Test Drug

    Belzutifan (MK-6482) Zanzalintinib (XL092)

Participate Sites
4Sites

Not yet recruiting1Sites

1 20 21 22 23 24 235
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB